Anna Kanerva

University of Helsinki — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

46h-index6.7kcitations310works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(224), CAR-T cell therapy research(144), Cancer Research and Treatments(107), Viral Infectious Diseases and Gene Expression in Insects(94), Ovarian cancer diagnosis and treatment(60)

Publications309 total

Supplementary Figure S5. from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S4 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S6 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S3 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S7 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Supplementary Figure S8 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
2025Open Access
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models
Cancer Immunology Immunotherapy·2025· 2 citedOpen Access
PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study
International Journal of Gynecological Cancer·2025· 2 citedOpen Access
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
Cancer Gene Therapy·2025· 2 citedOpen Access
Length of ischemic time is critical for accurate determination of homologous recombination capacity by immunostaining in FFPE tumor samples
2024Open Access
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors
Journal of Experimental & Clinical Cancer Research·2024· 13 citedOpen Access
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.
Journal of Clinical Oncology·2024· 1 cited
Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancer
2024· 4 citedOpen Access
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Cancer Gene Therapy·2023· 10 citedOpen Access
814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade
Regular and Young Investigator Award Abstracts·2023Open Access
806 Oncolytic adenovirus coding for human Mucin1 T cell engager with interleukin-2 potentiates anti-tumor T cell responses against tumors
Regular and Young Investigator Award Abstracts·2023Open Access
page 1 of 16Next →

Frequent Co-authors

Akseli Hemminki(48), Vincenzo Cerullo(16), Lotta Kangasniemi(14), David T. Curiel(13), Timo Joensuu(12), Iulia Diaconu(11), Minna Oksanen(11), Gerd Bauerschmitz(11), Kilian Guse(10), Merja Särkioja(10), Anniina Koski(9), Mari Raki(9), Tuuli Ranki(9), Leena Laasonen(9), Tanja Hakkarainen(9), Otto Hemminki(9), Sari Pesonen(9), Sophie Escutenaire(8), Mikko Siurala(8), Ronald D. Alvarez(7)